Twitter Facebook LinkedIn YouTube

Latest Video

Resverlogix has begun enrollment and dosing of patients in a Phase 2b clinical trial at a site at the University of Alberta Hospital in Edmonton, to evaluate the safety and efficacy of apabetalone as a potential oral treatment for COVID-19

Video Platform Video Management Video Solutions Video Player

Resverlogix has partnered with EVERSANA ™, a pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for COVID-19 in Canada and the United States.